About AXON

Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia, a condition characterized by significant decline in mental capacity and impaired daily function. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia, including Alzheimer's disease.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AXON is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 274.5 M 2.74518E+08 235 235 0.01% 8.80041E-05 53 K 52819
IBB iShares Nasdaq Biotechnology Index Fund 8.2 B 8.16892E+09 223 223 0.03% 0.0003 2.0 M 2036880
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 1.9 B 1.9E+09 1,012 1012 0.0% 9.45421E-06 18 K 18032
UBIO Proshares UltraPro Nasdaq Biotechnology 33.1 M 3.30601E+07 229 229 0.01% 5.97083E-05 6 K 6307

Wait, Before You Leave...